Journal: Cardiovascular Diabetology

Article Title: Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice

doi: 10.1186/s12933-016-0414-5

Figure Lengend Snippet: Linagliptin (LGT) has neutral effects on body weight and aortic advanced glycation end-products (AGE). a WD feeding for 4 months resulted in significant weight gain in both the cohorts. b Plasma DPP-4 activity was significantly decreased with LGT treatment. c AGE immunostaining in aorta was significantly increased in WDC. LGT treatment did not decrease it significantly. Quantification and representative images shown. Values are mean ± SE. CDC control diet control, CDL control diet linagliptin, WDC western diet control, WDL western diet linagliptin. Post-hoc comparisons within a time point; *p < 0.05 CDC vs WDC; # p < 0.05 CDC vs CDL; † p < 0.05 WDC vs WDL. Scale bars represent 50 mμ

Article Snippet: 20 μL plasma was diluted in DPP-4 assay buffer and substrate, 200 M H-Ala-Pro-AFC (I-1680; Bachem), was added.

Techniques: Activity Assay, Immunostaining, Western Blot

Journal: Cardiovascular Diabetology

Article Title: Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice

doi: 10.1186/s12933-016-0414-5

Figure Lengend Snippet: WD feeding causes a , b peri-aortic fibrosis and ( c , d ) medial thickening which is ameliorated by the DPP-4 inhibitor, LGT. a Picro sirius red and b Verhoeff-von Gieson staining. Values are mean ± SE. CDC control diet control, CDL control diet linagliptin, WDC western diet control and WDL western diet linagliptin. Post-hoc comparisons within a time point; *p < 0.05 CDC vs WDC; † p < 0.05 WDC vs WDL

Article Snippet: 20 μL plasma was diluted in DPP-4 assay buffer and substrate, 200 M H-Ala-Pro-AFC (I-1680; Bachem), was added.

Techniques: Staining, Western Blot

Journal: Cardiovascular Diabetology

Article Title: Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice

doi: 10.1186/s12933-016-0414-5

Figure Lengend Snippet: WD feeding induced aortic oxidative stress is ameliorated with DPP-4 inhibition. a 3-nitrotyrosine staining; b EC 3-nitrotyrosine; c VSMC 3-nitrotyrosine. Values are mean ± SE. CDC control diet control, CDL control diet linagliptin, WDC western diet control and WDL western diet linagliptin. Post-hoc comparisons within a time point; *p < 0 0.05 CDC vs WDC; † p < 0.05 WDC vs WDL

Article Snippet: 20 μL plasma was diluted in DPP-4 assay buffer and substrate, 200 M H-Ala-Pro-AFC (I-1680; Bachem), was added.

Techniques: Inhibition, Staining, Western Blot

Journal: Cardiovascular Diabetology

Article Title: Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice

doi: 10.1186/s12933-016-0414-5

Figure Lengend Snippet: WD feeding induced changes in FGF-23 and Klotho expression are restored by DPP-4 inhibition. a FGF-23 staining; b Endothelial FGF-23; c Adventitia FGF-23; d Endothelial klotho staining; e Endothelial klotho staining f Adventitia klotho staining; Average gray intensities in the different cohorts. Values are mean ± SE. CDC control diet control, CDL control diet linagliptin, WDC western diet control and WDL western diet linagliptin. Post-hoc comparisons within a time point; *p < 0 0.05 CDC vs WDC; † p < 0.05 WDC vs WDL; # p < 0.05 CDC vs CDL. Scale bars represent 50 mμ

Article Snippet: 20 μL plasma was diluted in DPP-4 assay buffer and substrate, 200 M H-Ala-Pro-AFC (I-1680; Bachem), was added.

Techniques: Expressing, Inhibition, Staining, Western Blot

Journal: Pharmacoeconomics

Article Title: A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus

doi: 10.1007/s40273-023-01268-5

Figure Lengend Snippet: Model parameters

Article Snippet: Van der Linden, 2020 [ ] , Netherlands , Dapagliflozin ?? mg 1d vs. DPP4 (represented by sitagliptin mainly) , AstraZeneca , Societal , 40 , Fixed-time increment stochastic simulation model , Cardiff , None stated , Triple therapy or above , MET+SU.

Techniques: Comparison, Injection, Filtration, Infection, Cell Counting

Journal: Pharmacoeconomics

Article Title: A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus

doi: 10.1007/s40273-023-01268-5

Figure Lengend Snippet: Cost-effectiveness and uncertainty results

Article Snippet: Van der Linden, 2020 [ ] , Netherlands , Dapagliflozin ?? mg 1d vs. DPP4 (represented by sitagliptin mainly) , AstraZeneca , Societal , 40 , Fixed-time increment stochastic simulation model , Cardiff , None stated , Triple therapy or above , MET+SU.

Techniques: Comparison

Journal: Pharmacoeconomics

Article Title: A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus

doi: 10.1007/s40273-023-01268-5

Figure Lengend Snippet: General characteristics of the studies

Article Snippet: Van der Linden, 2020 [ ] , Netherlands , Dapagliflozin ?? mg 1d vs. DPP4 (represented by sitagliptin mainly) , AstraZeneca , Societal , 40 , Fixed-time increment stochastic simulation model , Cardiff , None stated , Triple therapy or above , MET+SU.

Techniques: Comparison

Journal: Molecules

Article Title: Morpholine, Piperazine, and Piperidine Derivatives as Antidiabetic Agents

doi: 10.3390/molecules29133043

Figure Lengend Snippet: Piperazine-derived constrained compound as DPP-4 inhibitor.

Article Snippet: [ ] Medications for treatment type 2 diabetes include the same insulin drugs as shown above and also α-glucosidase inhibitors (acarbose and miglitol (Glyset by Pfizer, New York, NY, USA)), Biguanides (metformin (Glumetza by Santarus Inc., San Diego, CA, USA and Riomet by Sun Pharmaceutical Industries Inc., Mumbai, India)), Dopamine-2 agonists (Bromocriptine (Cycloset by Veroscience and Parlodel by Sandoz Pharmaceuticals Corp., Basel, Switzerland)), Dipeptidyl peptidase-4 (DPP-4) inhibitors (alogliptin (Nesina by Takeda Pharmaceuticals, Tokyo, Japan) and alogliptin-metformin (Kazano by Takeda Pharmaceuticals)), Glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonists) (dulaglutide (Trulicity), exenatide (Byetta by Amylin Pharmaceuticals, San Diego, CA, USA/Eli Lilly & Co.)), Sodium-glucose transporter (SGLT) 2 inhibitors (canagliflozin (Invokana by Janssen Pharmaceuticals, Beerse, Belgium)), Thiazolidinediones (rosiglitazone), and other (aspirin, medications for high cholesterol, and high blood pressure medications) [ ].

Techniques: Derivative Assay

Journal: Molecules

Article Title: Morpholine, Piperazine, and Piperidine Derivatives as Antidiabetic Agents

doi: 10.3390/molecules29133043

Figure Lengend Snippet: Sulfonyl piperazine derivatives as DPP-4 inhibitors.

Article Snippet: [ ] Medications for treatment type 2 diabetes include the same insulin drugs as shown above and also α-glucosidase inhibitors (acarbose and miglitol (Glyset by Pfizer, New York, NY, USA)), Biguanides (metformin (Glumetza by Santarus Inc., San Diego, CA, USA and Riomet by Sun Pharmaceutical Industries Inc., Mumbai, India)), Dopamine-2 agonists (Bromocriptine (Cycloset by Veroscience and Parlodel by Sandoz Pharmaceuticals Corp., Basel, Switzerland)), Dipeptidyl peptidase-4 (DPP-4) inhibitors (alogliptin (Nesina by Takeda Pharmaceuticals, Tokyo, Japan) and alogliptin-metformin (Kazano by Takeda Pharmaceuticals)), Glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonists) (dulaglutide (Trulicity), exenatide (Byetta by Amylin Pharmaceuticals, San Diego, CA, USA/Eli Lilly & Co.)), Sodium-glucose transporter (SGLT) 2 inhibitors (canagliflozin (Invokana by Janssen Pharmaceuticals, Beerse, Belgium)), Thiazolidinediones (rosiglitazone), and other (aspirin, medications for high cholesterol, and high blood pressure medications) [ ].

Techniques: